

26

27 **Main text**

28 Immune checkpoint blockade (ICB) with single-agent anti-PD1 (sICB) or combination anti PD-
29 1/anti-CTLA4 (cICB) monoclonal antibodies has transformed the clinical outlook for patients with
30 metastatic melanoma (MM)¹. However, clinical responses are variable and many patients develop
31 immune-related adverse effects (irAEs)^{2,3}. Whilst the relationship between peripheral CD8⁺ T cell
32 characteristics and clinical response of MM to ICB therapy is well described^{4,5}, myeloid responses
33 to ICB remain poorly defined. Existing work suggests that the circulating monocyte population
34 can modulate response to ICB, with an expanded monocyte population typically associated with
35 impaired clinical response to anti-PD1 therapy in both MM⁶ and non-small cell lung cancer
36 (NSCLC)⁷. Monocytes are conventionally categorised into three subsets: CD14⁺CD16⁻ classical
37 monocytes, CD14⁺CD16⁺ intermediate monocytes and CD14^{dim}CD16⁺ non-classical monocytes⁸.
38 In MM, small cohort studies have described relationships between monocyte subset counts to
39 response to both anti-PD1 and anti-CTLA4 treatment^{9,10}. There has been limited analysis of the
40 impact of standard-of-care combination anti-CTLA-4/anti-PD-1 treatment however, whilst the
41 impact of ICB on monocyte gene expression and relationships with clinical outcomes are similarly
42 unexplored.

43 We hypothesised that transcriptomic analysis of peripheral monocytes may provide
44 prognostic information and novel insights ICB-treatment response in patients with MM. We
45 assessed monocyte responses to ICB in isolated cells using bulk RNA-sequencing (RNA-seq)
46 across 116 individuals from a cohort of MM patients receiving ICB as well as samples from 45
47 healthy controls. We find MM is associated with distinct pro-inflammatory changes in monocyte
48 gene-expression, the extent of these correlating with baseline monocyte count and having
49 prognostic value. Treatment with either cICB or sICB therapies evokes shared patterns of gene

50 expression but no consistent change in counts of conventional subsets. We further characterised
51 heterogeneity in peripheral monocyte subsets in MM with scRNA-seq and flow cytometry, noting
52 relationships with clinical outcome, observing positive outcomes to be associated with an
53 expanded platelet binding subset whereas monocyte proliferation is associated with risk of early
54 death.

55

56 **RESULTS**

57 **Circulating monocytes in patients with metastatic melanoma have a distinct transcriptomic** 58 **profile**

59 To identify MM-associated signatures in circulating monocytes at baseline, we performed
60 differential gene expression (DGE) across monocytes from patients with MM versus healthy
61 donors (HD) (C1 n = 114 samples; HD n = 45 samples). This identified 1,774 significantly
62 differentially regulated transcripts in patient derived monocytes ($P_{\text{adj}} < 0.05$; Figure 1A,
63 Supplementary Table 1), including 871 upregulated, and 903 suppressed. Of note, genes encoding
64 the chemokine receptors CXCR1 and CXCR2, which bind to pro-inflammatory cytokine and
65 neutrophil chemoattractant IL-8, implicating pathways previously found to be associated with a
66 less favorable response to ICB¹², were markedly upregulated in MM patients (Figure 1B).
67 Interrogation of the Gene Ontology Biological Processes (GOBP) database¹³ identified key
68 expression pathways enriched in patient samples including chemotaxis (GO:0006935, $P_{\text{adj}} =$
69 0.0014; GO:0060326, $P_{\text{adj}} = 0.0096$), neutrophil degranulation (GO:0043312, $P_{\text{adj}} = 5.4 \times 10^{-14}$),
70 response to lipopolysaccharide (GO:0032496, $P_{\text{adj}} = 0.00027$), and vascular endothelial growth
71 factor (VEGF) signaling (GO:0048010, $P_{\text{adj}} = 0.02$) (Figure 1C, Supplementary Table 2). Given
72 increasing monocyte count is associated with poorer clinical outcome in melanoma⁶ and non-small
73 cell lung cancer (NSCLC)⁷, we examined the relationship between baseline monocyte gene

74 expression and pre-treatment hospital measured monocyte count. Strikingly, increasing monocyte
75 count was associated with markedly divergent expression profile, with 1,344 transcripts associated
76 with pre-treatment monocyte count (88 C1 samples, $P_{\text{adj}} < 0.05$; Figure 1D, Supplementary Table
77 3), of which 694 transcripts were positively associated with count, the most significant being
78 *FAM20A*, encoding a pseudokinase with putative roles in haematopoiesis¹⁴ (Figure 1E).
79 Conversely, increasing counts were negatively associated with 650 transcripts, most significantly
80 *IMPDH2*, encoding a gene involved in purine metabolism in response to hematopoietic stress¹⁵
81 (Figure 1E). Pathways positively correlated with monocyte count included neutrophil
82 degranulation (GO:0043312, $P_{\text{adj}} = 4.6 \times 10^{-20}$), as well as heterotypic cell-cell adhesion
83 (GO:0034113, $P_{\text{adj}} = 2.5 \times 10^{-3}$) and VEGF signaling (GO:0048010, $P_{\text{adj}} = 2.9 \times 10^{-3}$), whilst
84 suppressed pathways were mainly involved in rRNA processing (GO:0006364, $P_{\text{adj}} = 5.7 \times 10^{-23}$)
85 and DNA replication (GO:0006260, $P_{\text{adj}} = 7.0 \times 10^{-8}$) (Supplementary Table 4). Of particular
86 significance to cancer immunology was the negative association of IFNG regulated MHC class II
87 gene expression, crucial in antigen presentation, including *HLA-DRA* ($P_{\text{adj}} = 0.0005$), *HLA-DMA*
88 ($P_{\text{adj}} = 0.0063$), *HLA-DPA1* ($P_{\text{adj}} = 0.00057$) and *HLA-DPBI* ($P_{\text{adj}} = 0.0010$) with peripheral
89 monocyte count (Supplementary Table 3). In keeping with this, transcripts anti-correlated with
90 monocyte count were enriched for pathways including antigen presentation via MHC class II
91 (GO:0019886, $P_{\text{adj}} = 0.014$) and T cell co-stimulation (GO:0031295, $P_{\text{adj}} = 0.041$) (Supplementary
92 Table 4). Thus, an expanding circulating monocyte compartment is characterized by polarisation
93 towards an immature, mitotically active ‘classical monocyte’ phenotype with predisposition
94 towards heterotypic cell adhesion, VEGF mediated angiogenesis and reduced antigen presentation
95 function.

96

97 **ICB treatment modulates circulating monocyte gene expression**

98 To address the impact of ICB on monocytes, differential expression analysis between baseline
99 (pre-treatment, ‘C1’) and post-treatment (‘C2’) samples (n = 96 patients), controlling for age, sex
100 and treatment type (sICB/cICB) was performed in bulk monocyte RNA-seq data. This identified
101 a total of 1,067 significantly differentially modulated transcripts with ICB (758 induced, and 309
102 downregulated; $P_{\text{adj}} < 0.05$) (Figure 2A & 2C, Supplementary Table 5). ICB treatment robustly
103 induced type I and II interferon signaling (Figure 2A, Supplementary Table 5) including JAK-
104 STAT pathway members *STAT1* ($P_{\text{adj}} = 2.0 \times 10^{-7}$), *STAT2* ($P_{\text{adj}} = 3.0 \times 10^{-4}$), and *JAK2* ($P_{\text{adj}} = 1.4 \times 10^{-6}$).
105 The CXCL3 ligands *CXCL9* ($P_{\text{adj}} = 8.1 \times 10^{-9}$), *CXCL10* ($P_{\text{adj}} = 1.0 \times 10^{-8}$) and *CXCL11* ($P_{\text{adj}} =$
106 4.1×10^{-6}) were similarly induced. These IFN- γ induced transcripts are involved in CXCR3-
107 dependent immune cell chemotaxis and T_H1 polarisation^{16,17} and are associated with development
108 of irAEs^{18,19}. Similarly induced were transcripts encoding the classical complement proteins *CIQA*
109 ($P_{\text{adj}} = 3.6 \times 10^{-5}$), *CIQB* ($P_{\text{adj}} = 9.8 \times 10^{-5}$) and *CIQC* ($P_{\text{adj}} = 4.4 \times 10^{-5}$); MHC class II molecules
110 including *HLA-DRA* ($P_{\text{adj}} = 1.6 \times 10^{-4}$) and *HLA-DPBI* ($P_{\text{adj}} = 1.9 \times 10^{-5}$), as was *CD274* ($P_{\text{adj}} =$
111 2.8×10^{-9}), encoding PD-L1^{20,21} (Figure 2A, Supplementary Table 5). Correspondingly, ICB
112 induced transcripts were enriched across multiple pathways including IFN- γ -signaling
113 (GO:0060333, $P_{\text{adj}} = 2.5 \times 10^{-21}$), type I interferon-mediated signaling (GO:0060337, $P_{\text{adj}} = 9.8 \times 10^{-12}$),
114 antigen presentation via MHC class I (GO:0002479, $P_{\text{adj}} = 2.5 \times 10^{-21}$) and class II
115 (GO:0019886, $P_{\text{adj}} = 0.0069$), and T cell co-stimulation (GO:0031295, $P_{\text{adj}} = 1.5 \times 10^{-4}$) (Figure 2D,
116 Supplementary Table 6). Expression of signaling pathways including tumour necrosis factor
117 (TNF) (GO:0033209, $P_{\text{adj}} = 2.5 \times 10^{-10}$) and NF κ B signaling (GO:0043123, $P_{\text{adj}} = 5.3 \times 10^{-3}$) were
118 also enriched in monocytes following ICB (Figure 2D, Supplementary Table 6).

119 Comparative analysis of monocyte responses to cICB versus sICB demonstrated that, as per CD8
120 T cells⁴, cICB was associated with a greater magnitude of transcriptional modulation, with 2,777
121 transcripts differentially expressed with cICB (pairwise analysis, n=51 patients) but only 85

122 following sICB (pairwise analysis, n=45 patients) (Figure 2B, 2C, Supplementary Figure 1,
123 Supplementary Tables 7 & 8). There was near complete concordance of the transcripts modulated
124 by cICB versus sICB (80/85 transcripts) and sICB and cICB demonstrated consistent shared
125 direction of effect, but greater magnitude of transcriptional modulation with cICB (Figure 2C, 2E).
126 A total of 352 transcripts (240 induced, 112 suppressed) were preferentially regulated in
127 monocytes with cICB compared to sICB. Preferentially cICB induced transcripts included *CD274*
128 ($P_{\text{adj}} = 0.0033$), *CXCL10* ($P_{\text{adj}} = 6.3 \times 10^{-3}$), *CXCL11* ($P_{\text{adj}} = 0.042$), and *CIQC* ($P_{\text{adj}} = 0.019$)
129 (Supplementary Table 9) and corresponding pathway analysis of these genes again highlighted
130 enrichment of type I IFN and IFN- γ -related signaling, JAK-STAT and T cell receptor signaling
131 (Figure 2F, Supplementary Table 10). This suggests that, as with CD8⁺ T cells⁴, cICB is associated
132 with a qualitatively similar but quantitatively greater transcriptional effect on peripheral monocytes.

133

134 **Peripheral monocyte transcriptomic profiles predict clinical outcome**

135 We then identified monocyte-expressed markers of clinical response by performing differential
136 expression analysis of bulk RNA-seq data with clinical outcome parameters. Clinical parameters
137 including risk of death at three, six and twelve months after date of first treatment, and progression
138 at six-months were used to dichotomise patients, with differential expression analysis controlled
139 for age, sex and, where applicable, treatment type and cycle. We found a monocyte cycling
140 signature characterised by expression of proliferation index marker *MKI67* to be associated with
141 death at all three time points (Figure 3A-C, Supplementary Tables 11-13) with 314, 239 and 444
142 transcripts associated with death at three, six and twelve months respectively (controlling for age,
143 sex, treatment status and type across 114 C1 and 98 C2 patient samples, $P_{\text{adj}} < 0.05$) (Figure 3A-C,
144 Supplementary Tables 11-13). Transcripts across all time points positively correlated with death
145 were enriched for pathways associated with the monocyte MM-associated expression signature we

146 describe above, including neutrophil degranulation (GO:0043312), platelet degranulation
147 (GO:0002576) and response to LPS (GO:0032496) (Figure 3E, Supplementary Table 14-16).
148 Strikingly, when we explored this by treatment status, risk of death was primarily related to pre-
149 treatment samples (Supplementary Figure 2, Supplementary Table 17A-C). We also found 269
150 transcripts associated with progression at six months (113 C1 samples and 98 C2 controlling for
151 treatment type, status, age and sex, $P_{\text{adj}} < 0.05$) (Figure 3D, Supplementary Table 18A) which were
152 enrichment for pathways including angiogenesis (GO:0001525) (Supplementary Table 18B).
153 These observations indicate previously undescribed mechanisms through which the prognostic
154 effects of peripheral monocytes and elevated counts are mediated.

155

156 **Dissecting heterogeneity in monocyte subgroup responses to ICB**

157 Monocytes are heterogeneous in composition but are conventionally categorized into three subsets:
158 CD14⁺CD16⁻ classical monocytes, exhibiting prominent chemotactic properties, CD14^{dim}CD16⁺
159 non-classical monocytes implicated in antibody dependent cellular cytotoxicity (ADCC)²³; and
160 CD14⁺CD16⁺ intermediate monocytes, characterized by prominent MHC class II expression²⁴. We
161 used flow-cytometry to explore monocyte populations pre and post ICB, finding no significant
162 change in any subset size with treatment (n = 53 paired samples) (Figure 4A), this observation
163 remaining when performing sICB and cICB specific analysis (Supplementary Figure 3). Notably,
164 survival analysis showed that a larger proportion of cytometry-identified non-classical monocytes
165 at both baseline and following treatment was associated with prolonged overall survival (OS) (at
166 baseline C1 $P = 0.0079$; post-treatment C2, $P = 0.0016$, log-rank tests) and extended progression
167 free survival (PFS) ($P = 0.014$ at C1, post-treatment C2: $P = 0.02$, log-rank test) (Figure 4B).
168 Conversely, consistent with the hospital blood monocyte count, increasing monocyte proportion
169 as a total of peripheral blood mononuclear cells (PBMCs) pre-treatment was associated with

170 reduced OS (pre-treatment, $P= 0.014$, log-rank test), and post-ICB reduced PFS and OS (post-
171 treatment PFS $P = 0.028$; OS, $P= 0.031$, log rank test) (Figure 4C). In keeping with previous
172 studies²⁵, a higher lymphocyte to monocyte ratio (LMR) at baseline was associated with extended
173 OS ($p = 0.035$, log-rank) (Supplementary Figure 3).

174

175 **Characterising peripheral monocytes with scRNA-seq**

176 To further characterize the predictive role of monocyte subsets, we performed scRNA-seq of
177 monocytes from peripheral blood both pre- and post-ICB treatment from eight patients with MM,
178 as well as three healthy donors (Supplementary Figure 4). Unsupervised clustering of cells across
179 all conditions was performed to a high resolution i.e. ‘overclustering’, and comparison with
180 publicly available annotated expression datasets using *SingleR* (Supplementary Figure 4) was
181 performed. Monocyte groups present across all conditions/patients were selected for downstream
182 analysis (Supplementary Figure 5) and a total of 22,116 cells were analysed. Two main monocyte
183 subsets were identified: those aligned to a classical monocyte annotation, and those annotated as
184 an intermediate/non-classical *FCGR3A*-expressing ‘CD16⁺ monocyte’ group (Figure 5A,
185 Supplementary Figure 5). The large classical-like monocyte cluster was characterised by markers
186 including *CD14* ($P_{\text{adj}}= 5.3 \times 10^{-251}$), and genes involved in adhesion and migration including
187 *CLEC4E*²⁹ ($P_{\text{adj}}= 6.6 \times 10^{-67}$), *VCAM*³⁰ ($P_{\text{adj}} < 1 \times 10^{-300}$), *CCR2*^{29,31} ($P_{\text{adj}}= 2.0 \times 10^{-66}$) and *SELL*²⁹ (P_{adj}
188 $= 1.0 \times 10^{-94}$) (Supplementary Figure 6, Supplementary Table 20). Pathway enrichment included
189 response to lipopolysaccharide (GO:0032496) and response to wounding and wound healing
190 (GO:0009611, GO:0042060) (Supplementary Figure 6, Supplementary Table 22). CD16⁺
191 monocytes were defined by expression of *FCGR3A* ($P_{\text{adj}} < 1 \times 10^{-300}$), *TNF* ($P_{\text{adj}}= 6.2 \times 10^{-52}$),
192 classical complement genes *CIQA* ($P_{\text{adj}}= 2.2 \times 10^{-167}$), *CIQB* ($P_{\text{adj}}= 1.51 \times 10^{-116}$), and *CIQC* ($P_{\text{adj}}=$
193 4.7×10^{-83}) and interferon-induced genes including *IFITM1* ($P_{\text{adj}}= 5.8 \times 10^{-181}$), *IFIT2* ($P_{\text{adj}}= 2.2 \times 10^{-$

194 ²²), and *IFIT3* ($P_{\text{adj}} = 7.3 \times 10^{-73}$) (Supplementary Table 20), these genes being enriched for T cell
195 co-stimulation (GO:0031295), T cell receptor signaling (GO:0050852), and antigen processing
196 and presentation via MHC-class II pathways (GO:0019886) (Supplementary Table 22) pathways.

197

198 We did not identify a distinct intermediate monocyte population on high-level unsupervised
199 clustering, however unsupervised clustering of the large classical monocyte compartment revealed
200 further heterogeneity within it. We found the classical monocyte compartment could be further
201 divided into four distinct sub-clusters: ‘Classical1’ characterised by high expression of alarmin
202 complex genes *S100A8/A9*; ‘Classical2’ with high expression of *CD14* and *EGRI*, a key inhibitory
203 regulator of myeloid populations²⁸; ‘Classical3’ with robust expression of an IFN-response
204 associated signature including *GBP1*, *GBP2*, and *STAT1*; and ‘Classical4’ which had a distinct
205 monocyte-platelet aggregate (MPA)-like classical profile with high expression of platelet-
206 associated genes including *PPBP* ($P_{\text{adj}} = 9.5 \times 10^{-159}$) which encodes chemokine and
207 *CXCR1/CXCR2* ligand *CXCL7* in activated platelets²⁶, and *GP9* ($P_{\text{adj}} = 2.3 \times 10^{-38}$), a von
208 Willebrand factor receptor required for clotting²⁷ (Figure 5A & 5B, Supplementary Table 19).
209 Pathway enrichment analysis of group-defining markers demonstrated overlap between groups,
210 but Classical1 was characterised by enrichment of antimicrobial humoral response pathway,
211 Classical2 for phagocytosis, Classical3 for defense response to virus, antigen processing via MHC
212 class II and T cell co-stimulation (Figure 5C, Supplementary Table 21) whilst Classical4 was
213 enriched for platelet activation and blood coagulation pathways (Figure 5C, Supplementary Table
214 21). Notably, although power to detect ICB related subset size changes was limited, we found no
215 significant change in the proportion of classical, $CD16^+$ or classical subgroups (Classical₁ –
216 Classical₄) with ICB (Supplementary Figure 7), in keeping with flow-cytometry observations.

217

218 We performed analysis of monocytes according to expression of gene sets consisting of the most
219 significantly associated transcripts of a candidate ‘hub gene’ (Supplementary Figure 8). Both
220 antigen-presentation and complement module scores comprised genes characteristic of non-
221 classical monocytes such as *FCGR3A*, *CDKN1C* and MHC Class II genes (Supplementary Tables
222 23-28). The chemotaxis score comprised a classical expression signature. CD16⁺ monocytes had
223 higher expression antigen-presentation, complement production, and IFN signaling modules,
224 whilst classical monocytes exhibited higher expression of chemotaxis-associated gene modules
225 (Figure 5D). Expression module scoring revealed a continuum of activation states across the
226 classical subgroups, with Classical1 and Classical2 exhibiting low complement and antigen
227 presenting expression module scores, and Classical3 expressing higher expression of these
228 modules (Figure 5D).

229
230 Having defined monocyte transcriptional heterogeneity with scRNA-seq in a subset of patients,
231 we determined to explore the clinical correlates of the identified subset associated expression
232 signatures across the full cohort. Intriguingly, we found that expression above the median of the
233 MPA expression signature (Classical4) at baseline was associated with improved clinical outcomes
234 to ICB with significant associations to PFS ($p = 0.011$, log-rank median PFS low MPA: 5.5 mnths
235 (95% CI 15.2 – 30.2), median PFS high MPA: 35.1 mnths (95% CI 28.1 – 43.1) and OS ($P =$
236 0.025 , log-rank, mean OS low MPA: 25.0 mnths (95% CI 28.1 – 43.1), median OS high MPA:
237 53.3 mnths (95% CI 38.4 – 52.3)) (Figure 5E).

238

239 **DISCUSSION**

240 Cancer has been associated with altered transcriptional profiles in monocytes with upregulation of
241 chemotaxis pathways^{32–35}, impaired cytotoxicity³⁶, polarisation towards an immature phenotype³⁷

242 and altered metabolic pathways^{9,32}. Here we show in the analysis of a large patient cohort that MM
243 likewise has distinct effects on monocyte expression profiles, with induction of chemotaxis,
244 adhesion and angiogenesis-associated pathways. An elevated monocyte count has been associated
245 with poor prognosis across cancer types³⁸⁻⁴¹. For the first time we show that a raised monocyte
246 count is accompanied by profound changes in monocyte transcriptional profiles, indicating
247 mechanisms through which the prognostic effects of elevated monocytosis may be mediated.
248 Specifically, as well as increased expression of mitotic factors, there is upregulated VEGF
249 expression, indicating the emergence of a cycling, immature pro-angiogenic ‘classical-type’
250 expression profile.

251 We provide novel insights into the effects of ICB treatment on immunity. Using bulk monocyte
252 RNA-seq data from a large MM cohort we demonstrate that ICB promotes a monocyte
253 transcriptional profile in keeping with a T cell costimulatory phenotype, with upregulation of
254 antigen presentation via MHC class II pathways, classical complement and pro-inflammatory
255 cytokines. Notably, *CXCL9*, *CXCL10* and *CXCL11* are all robustly upregulated in monocytes by
256 ICB. The *CXCL9-11/CXCR3* axis is implicated in immune migration and the development of Th1
257 cells¹⁷ whilst the myeloid *CXCR3-CXCL9/10/11* axis has a key role in modulating CD8⁺ T cell
258 responses in the context of ICB⁴². Induction of this axis in macrophages following cICB is also
259 described, with *CXCL9*-expressing macrophages required for CD8⁺ T cell infiltration and for
260 effective clinical response⁴³. Here we extend these observations from murine tumour based
261 myeloid cells, demonstrating activation of this axis in circulating monocytes in patients, indicating
262 that monocytes may play an early role in modulating peripheral CD8⁺ T cell recruitment. Notably,
263 as in CD8⁺ T cells, although it is qualitatively concordant the magnitude of transcriptional response
264 is far greater with cICB versus sICB⁴. Given the dosing of nivolumab in cICB is 1mg/kg as
265 opposed to fixed monthly dosing of 480mg, patients typically receive much less anti-PD-1

266 treatment at the outset of this regimen. This marked divergence in transcriptional responses
267 between sICB and cICB attests to a highly significant synergistic effect of the addition of
268 ipilimumab and may reflect the greater propensity for cICB to both induce irAEs as well as long-
269 term durable disease control. Interestingly, despite marked transcriptional changes, consistent
270 shifts in the size of monocyte proportion or classical and non-classical populations were not seen
271 in response to ICB in our dataset, potentially indicating a peripheral ‘steady state’ following ICB
272 in early post-treatment timepoints.

273
274 Expansion of circulating monocytes is associated with a less favourable clinical outcome across
275 different malignancies⁴⁴⁻⁴⁷. In keeping with previous reported associations, we find that a smaller
276 monocyte population both before and after ICB is associated with better clinical outcome, as is a
277 higher pre-treatment lymphocyte to monocyte ratio. However, intra-compartmental heterogeneity,
278 polarization and activity also appears significant. We show that a monocyte cycling signature
279 (inferred by *MKI67* expression) with enrichment of MM-associated ‘classical-type’ signature at
280 baseline is predictive of early death. We also explore the role of monocyte subsets in this context.
281 A larger non-classical monocyte subset, both at baseline and following treatment, is associated
282 with a more favourable prognosis. This suggests that response to ICB is determined in part by
283 baseline characteristics in circulating monocytes, with an immature classical ‘cycling’ signature a
284 poor prognostic signature, and a non-classical population associated with more favourable
285 response to ICB. This may be underpinned by the T cell co-stimulatory phenotype and effects of
286 pro-inflammatory non-classical monocytes.

287 We use scRNA-seq to dissect the roles of monocyte subsets in predicting response to ICB. Whilst
288 there are three conventionally recognised monocyte subsets, scRNA-seq studies are notable for the
289 discrepancy and variety of described subsets⁴⁸⁻⁵¹. However, in keeping with most studies, we

290 identify a large classical subset, and smaller CD16+ subset. We isolated monocytes for scRNA-
291 seq with magnetic bead sorting using CD14 antibodies, and this potentially enriched for classical
292 monocytes, allowing us to describe the transcriptional heterogeneity within this compartment. In
293 keeping with this, our unsupervised clustering of scRNA-seq data identifies four sub-clusters
294 within the classical subset. Notably, we observe one, Classical4, with expression profiles
295 consistent with an MPA-associated signature. Applying the expression signature of this subset
296 cohort-wide across the bulk monocyte RNAseq data demonstrates that increased pre-treatment
297 expression of this geneset is associated with a more favourable prognosis. Whether this reflects a
298 genuine subset of increasingly reactive monocytes or alternatively, is a proxy marker for anti-
299 tumour monocyte or platelet activity is unclear and requires analysis in larger single-cell datasets
300 currently being generated. Notably MPA are described across multiple conditions and have been
301 associated with poor prognosis in cardiovascular disease⁵² and COVID-19⁵³. Monocyte-platelet
302 adhesion enhances CD16 expression and promotes a pro-inflammatory phenotype in circulating
303 monocytes⁵⁴. In the context of cancer this monocyte ‘stickiness’ at baseline may predict propensity
304 to polarisation towards a pro-inflammatory myeloid response with T cell costimulatory effects.
305 A limitation of this work is the extent to which the changes we observe in monocyte expression in
306 response to ICB therapy reflect ICB induced T cell activation, versus direct modulation of
307 monocytes on T cell activation. Our analyses of CD8⁺ T cells in patients with MM has provided
308 critical insights into how T cell responses and clonal dynamics reflect clinical response to ICB and
309 confirmed the potential role for peripheral immune signatures as clinical predictive biomarkers^{4,5}.
310 Further work to dissect this interaction in larger datasets at single-cell resolution will be key to
311 fully understanding the mechanism of immune modulation of ICB treatment across individuals
312 and the relationship with clinical response. Nonetheless, our analysis describes favourable
313 associations with clinical outcome of increased counts of non-classical monocyte subsets as

314 defined by flow-cytometry. Conversely, we find that the increased monocytosis frequently
315 observed in MM is associated with profoundly pro-inflammatory and pro-angiogenic expression
316 profiles of monocytes in this state, with a presumed pro-tumourogenic effect, and indicating a
317 causal role in impaired response to ICB and early death in MM.

318

319 **MATERIALS AND METHODS**

320 **Samples**

321 Peripheral blood samples were obtained from patients \geq 18 years old with metastatic melanoma
322 (MM) treated with immune checkpoint blockade (ICB). This included patients treated with
323 ipilimumab/nivolumab (anti-CTLA-4/PD-1) combination immune checkpoint blockade (cICB),
324 and with single-agent pembrolizumab or nivolumab (anti-PD-1) immune checkpoint blockade
325 (sICB). All patients provided prior written informed consent for samples to be donated to the
326 Oxford Radcliffe Biobank (Approved by South Central – Oxford C Research Ethics Committee
327 12th April 2019, REC Reference 19/SC/0173 with internal Oxford Centre for Histopathology
328 Research ethical approval, 16/A019, 18/A064) to be used for research. Peripheral blood samples
329 were obtained prior to the first treatment dose (cycle ‘C1’, day0), and then just before the second
330 dose (cycle 2, C2, day21). ICB treatment regimes were according to standard treatment protocols.
331 For patients receiving cICB this involved administration of ipilimumab and nivolumab every three
332 weeks for up to four doses. For patients treated with sICB, pembrolizumab was administered once
333 every three weeks, or every four weeks for nivolumab. Up to 50 ml of peripheral blood was
334 collected per sample in ethylenediaminetetraacetic acid (EDTA) tubes. Control samples were
335 obtained from the Oxford biobank after informed written consent was obtained. Samples were
336 collected with local ethical approval (REC 06/Q1605/55).

337

338 **Clinical Data**

339 Clinical outcome data across the cohort was obtained, including parameters such as progression at
340 six months, time-to-progression, overall survival (OS), progression free survival (PFS) and death
341 status. OS was defined as the time between the start date of ICB treatment to death, whilst PFS
342 was defined as time between the first ICB dose and disease progression according to either death
343 or disease progression on imaging. Clinical outcome data was available for 114 samples at baseline
344 (C1) and 98 post-treatment (C2) samples.

345

346 **Bulk RNA Sequencing**

347 Bulk RNA-seq was carried out on CD14⁺ cells from 45 healthy donors, and 116 MM patients
348 treated with ICB. Patients receiving adjuvant ICB were excluded from analysis. A total of 114 C1
349 (day0) and 98 C2 (day21) samples were sequenced, including from 91 patients with paired pre and
350 post treatment data. Bulk RNA-seq libraries were sequenced in three batches. The first RNA cohort
351 was sequenced using 75 bp paired-end sequencing on an Illumina Hiseq-4000 platform. The
352 second cohort was sequenced using the Illumina NovaSeq platform with 150 bp paired-end
353 sequencing. The third batch of samples was run on a NovaSeq6000 platform using 150 bp paired-
354 end sequencing. The bulk RNA-seq was performed at the Oxford Genome Centre, Wellcome
355 Centre for Human Genetics. *HISAT2*⁵⁵ was used to align reads in FASTQ files to the GRCh38/hg38
356 genome build. Adequately mapped reads were identified according to MAPQ score with *bamtools*.
357 *Picard* was used to remove duplicate reads. *HTseq*⁵⁶ was used to generate read count data.

358

359 **Differential expression analysis**

360 Differential expression analysis of bulk RNA-seq data was carried out using *DESeq2*¹¹. *DESeq2*
361 was used to normalise read counts. The *ComBat-seq*⁵⁷ package was used to remove the effect of
362 batch sequencing.

363 For differential expression analysis of transcripts expressed across healthy donors ('HD' or 'C')
364 versus pre-treatment samples, variables including sex and sex were included in the *DESeq2* design
365 argument (i.e. design = ~ sex + age + cycle). Transcripts were filtered and only those with a mean
366 count > 10 were selected for differential expression analysis. Differential expression analysis was
367 performed using a binomial Wald test. The Benjamin-Hochberg (BH) method was used to correct
368 for multiple testing to identify significantly differentially expressed transcripts ($P_{adj} < 0.05$).

369 To identify transcripts in CD14⁺ cells associated with clinical outcome parameters, differential
370 expression analysis was used, dichotomising clinical outcome data, either into those who had
371 disease progression at six months, versus those who did not progress; and those who died three,
372 six and twelve months after starting ICB treatment, versus those that did not. *DESeq2* was used to
373 perform differential expression analysis, controlling for treatment state and type (sICB or cICB)
374 where applicable, as well as age and sex.

375

376 **Pathway enrichment analysis**

377 The *XGR*⁵⁸ package was used for pathway enrichment analysis using interrogation of the GOBP
378 database. Unless otherwise stated, induced/suppressed or positively/negatively associated
379 transcripts were analysed separately.

380

381 **scRNA-seq samples**

382 scRNA-seq library preparation and sequencing was performed as previously described^{4,5}. In the
383 first batch, CD8⁺ and CD14⁺ cells were isolated from PBMCs from peripheral blood from four

384 patients treated with ipilimumab/nivolumab combination-immune checkpoint blockade (cICB)
385 and four treated with pembrolizumab single-immune checkpoint blockade (sICB). Samples were
386 obtained before (C1, day0) and after (C2, day21) the first treatment cycle. Healthy donor samples
387 from three individuals were pooled prior to library preparation and sequenced in a second batch.

388

389 **scRNA-Seq library preparation**

390 The Chromium 10x platform was used for scRNA-seq library preparation. scRNA-seq data was
391 prepared in two batches. In the first batch, 6000 of both CD8⁺ and CD14⁺ cells were combined
392 in suspension (total number 12,000 cells). In the second batch, 2000 CD14⁺ cells from each of
393 three healthy donors were mixed in suspension in a single well. 5' transcriptome processing was
394 performed using the Chromium 10x system. Samples were processed according to standard
395 manufacturer's protocols⁵⁹. This involved initial barcoding with a unique tag, reverse transcription,
396 cDNA amplification and library preparation.

397 For the first batch, 5' transcriptome library sequencing was performed using a HiSeq platform with
398 75bp paired-end sequencing with a depth of at least 50,000 reads per cell. The healthy donor
399 control samples were sequenced using a NovaSeq 6000 platform with 150 bp paired-end
400 sequencing with a mean sequencing depth of 78,000 reads per cell. The *Cellranger* package was
401 used to process scRNA-seq data⁶⁰. The *Cellranger mkfastq* was used to produce FASTQ files from
402 the Illumina BCL files. *Cellranger count* was then applied to each FASTQ file to produce a feature
403 barcoding and gene expression library. *Cellranger mkfastq*, *count* and *aggr* were used to combine
404 samples for merged downstream analysis.

405

406 **scRNA-seq quality control**

407 For quality control (QC), the *scater* package⁶¹ was used to remove outliers, and *scran*⁶² package
408 was used to remove doublets. Cells were then selected based on *CD14* expression, with those cells
409 expressing *CD8A*, *CD3D*, *CD3E*, *CD3G*, *CD56*, *CD19* or *CD20* removed from downstream
410 analysis to remove possible contaminants. QC was then performed by removing cells that had
411 fewer than 300 different features (genes), fewer than 500 UMIs (transcripts) and those whereby
412 more than 20% of expressed genes were mitochondrial. Genes expressed in fewer than five cells
413 were also removed from downstream analysis.

414

415 **Clustering analysis**

416 The *Seurat*⁶³ package in R was used for downstream analysis of the scRNA-seq data. The raw gene
417 expression matrix was normalised and then subject to *FindVariableFeatures* function⁶³. Both
418 untreated and treated samples were merged following normalisation. Integration anchors between
419 MM patient and Healthy donor (Control) data sets were identified using *FindIntegrationAnchors*
420 and integration of the patient and Control datasets was performed with *IntegrateData* function.
421 Data was then scaled, and then a principal component analysis was run using the first 13
422 dimensions. This level of dimensionality was chosen as it was the level at which the variation
423 between consecutive principal components was minimal as seen on an *Elbowplot*. Unsupervised
424 clustering was performing using the *FindClusters* function and the clusters visualised using a
425 uniform manifold approximation and projection (UMAP) plot.

426 The *clustree*⁶⁴ package was used to visualise monocyte clustering trees at resolutions of 0.1, 0.2
427 0.25, 0.5, 0.75, 1,2 and 3 (at 13 dimensions). To perform annotation of monocyte clusters with
428 published gene sets the *singleR*⁶⁵ package was used to compare the scRNA-seq data to annotated
429 expression datasets including the Human Primary Cell Atlas dataset⁶⁶, MonacoImmune dataset⁶⁷,
430 Immune Cell Expression data set⁶⁸ and scRNA-seq data published by Villani et al⁴⁸. Only groups

431 found across all conditions and patients were used for downstream analysis. As such, cluster 5 was
432 removed from downstream analysis as it was present only in patient ID7 post-treatment and in
433 controls.

434

435 **Identification of cluster-defining markers**

436 To identify genes differentially expressed in monocyte cluster the *FindAllMarkers* function was
437 used to find differentially expressed genes between a single subset and the remaining data,
438 selecting only positively expressed transcripts with the default Wilcoxon signed-rank sum test.
439 The logFC threshold was set to $-\text{Inf}$ and a method based on Bonferoni adjustment was used to
440 correct for multiple testing.

441

442 **Gene expression module scoring**

443 To calculate the phenotype scores (e.g. immaturity, complement, antigen presenting scores), the
444 Seurat *AddModuleScore* function was utilised to assign a score indicating the average expression
445 of a defined gene set per single cell. The gene sets used for module scoring applied to each cell
446 were identified by selecting the top 50 genes most significantly correlated with hub genes of
447 interest such as *CD14*, *CIQA*, and *HLA-DR* expression. To identify significantly correlated
448 transcripts, Pearsons correlation analysis was performed across all single cells and across Variable
449 feature genes (n=2000) using the *Hmisc* package in R, adjusting for multiple testing using the
450 Holm's method with the *RcmdrMisc* function. Hub genes were selected based on association with
451 a particular phenotype or function. For example, *FCGR3A* was selected as a hub gene indicative
452 of non-classical phenotype.

453

454 **Subset scoring in bulk RNA-seq data**

455 We identified the 20 most highly expressed genes identified using *FindAllMarkers* definitive of
456 each monocyte cluster and the geometric mean score of this gene set across each *DESeq2*-
457 normalised bulk RNA-seq patient sample was calculated. Association between this expression
458 signature and clinical outcome data was performed using the *survminer* and *survival* packages to
459 perform survival analysis.

460

461 **Flow cytometry**

462 Following separation, PBMCs were stored in liquid nitrogen in 90% FCS and 10% dimethyl
463 sulfoxide (DMSO). Samples were thawed and then 1×10^6 PBMCs were placed into a solution of
464 HBSS with 5% FCS on ice. After 30 mins cells were fixed in 2% formaldehyde. Samples were
465 stained using a fixable amine-reactive viability dye (LIVE/DEAD Fixable Near-IR Dead Cell Stain
466 Kit). The appropriate antibodies were added to the sample as outlined below. The flow cytometry
467 was carried out with a LSRII (Becton Dickinson) platform. FlowJo software was used to analyse
468 cells blinded to clinical outcome data. For gating, myeloid cells were identified using FSC-A and
469 SSC-A, excluding doublets. Dead/dying cells were removed via the selection of viability stain
470 negative cells. Monocytes were then selected based on CD14 expression, and then classical,
471 intermediate and non-classical monocytes were gated according to relative CD14/CD16
472 expression.

473

Antibody/stain	Fluorochrome	Clone	Dilution	Source
Live/Dead cell stain kit	Near-IR	n/a	1000	ThermoFisher Scientific
CD14	PE/Cy7	M5E2	50	BioLegend

CD16	FITC	3G8	50	BioLegend
------	------	-----	----	-----------

474

475 **Survival analysis**

476 The *survminer* and *survival* packages were used to perform survival analysis (exploring
477 association with OS and PFS) and visualise Kaplan-Meier curves. Samples were dichotomised
478 into two subsets according to variable of interest e.g expression score, being above or below the
479 median value. A log-rank test was used to determine statistical significance.

480

481 **Statistical analyses**

482 All statistical analyses were performed within the R package (v 4.2.2). Plots were created using
483 *ggplot2*. Boxplots demonstrate the upper and lower quartiles, with the line in the middle indicating
484 the median, and Tukey's whiskers indicating the range. Unless otherwise states, a Wilcoxon
485 signed-rank test was used to test for significance.

486

487 ***Figure 1: Peripheral monocytes exhibit distinct transcriptomic profiles in patients with*** 488 ***metastatic melanoma***

489 *1A) Volcano plot to show significantly differentially expressed genes between MM patients at*
490 *baseline ('C1') and healthy donors (HD) (114 C1 samples, 45 healthy controls, DESeq2 analysis*
491 *controlling for age and sex ($P_{adj} < 0.05$). B) Boxplot to show $\log_2(CXCR1)$ and $\log_2(CXCR2)$*
492 *expression in monocytes in MM patients at baseline (C1) versus healthy donors (HD). C) Dot plot*
493 *to show key enriched and suppressed GOBP pathways in monocytes in MM patients versus healthy*
494 *controls ($P_{adj} < 0.05$). D) Volcano plot to show monocyte expressed transcripts associated with*
495 *baseline peripheral monocyte count (DESeq2 analysis, controlling for age and sex, 88 C1*

496 *samples, $P_{adj} < 0.05$). E) Scatterplot to show correlation between monocyte expression of FAM202*
497 *and IMPDH2 and peripheral monocyte count at baseline (C1) (Pearson's correlation).*

498

499 **Figure 2: Transcriptional responses to ICB in circulating monocytes**

500 *Volcano plot to show differentially regulated transcripts in response to: A) ICB across cICB and*
501 *sICB treated patients (DESeq2 controlling for age, sex and treatment type (sICB or cICB), $n = 96$*
502 *patients, $P_{adj} < 0.05$) and B) cICB (DESeq2 pairwise analysis, 51 patients). C) Barplot to show*
503 *number of induced/suppressed transcripts with ICB (Both sICB and cICB treated patients, $n = 96$*
504 *patients, sICB $n=45$ patients and cICB $n= 51$ patients). D) Dot plots to show key significantly*
505 *enriched GOBP pathways induced and suppressed with ICB across all patients ($P_{adj} < 0.05$). E)*
506 *Plot to show correlation between \log_2 fold change (FC) of transcripts significantly differentially*
507 *expressed with cICB (' \log_2FC_cICB ') versus the \log_2 fold change of those same transcripts*
508 *following sICB (' \log_2FC_sICB ') (Pearson's correlation). F) Dot plot to show key preferentially*
509 *enriched GOBP pathways with cICB versus sICB ($P_{adj} < 0.05$).*

510

511 **Figure 3: Transcriptional correlates of clinical response in peripheral monocytes**

512 *Volcano plot to show transcripts associated with death at: A) three months; B) six months and C)*
513 *twelve months after the date of commencing of the first cycle of ICB treatment (DESeq2 analysis,*
514 *controlling for age, sex, treatment status and treatment type, 114 C1 patients, 98 C2 patients, P_{adj}*
515 *< 0.05). D) Volcano plot to show transcripts associated with disease progression at six months*
516 *(DESeq2 analysis, controlling for age, sex, treatment status and treatment type, 113 C1 patients,*
517 *98 C2 patients, $P_{adj} < 0.05$). E) Dot plot to show selected GOBP pathways enriched across*
518 *transcripts associated with risk of death at three months ($P_{adj} < 0.05$).*

519

520 **Figure 4: Monocyte heterogeneity and immune checkpoint blockade responses**

521 A) Boxplots to show monocyte subsets (classical, intermediate and non-classical) as a proportion
522 of the total peripheral monocyte population as assessed by flow cytometry across 53 paired C1
523 and C2 patient samples (paired Wilcoxon signed-rank test). Points are coloured by treatment type
524 (cICB = red, sICB = blue). B) Kaplan-Meier curve to show non-classical monocyte subset size as
525 a proportion of monocyte population above/below median) and overall survival (OS) (C1, n=57,
526 C2, n=59) and progression free survival (PFS) (57 C1, 59 C2 samples) (log-rank test). C) Kaplan-
527 Meier curve to show total monocyte subset size as a proportion of all PBMCs on flow cytometry
528 above/below median) and OS at baseline at C1 (n = 57 patients, log-rank tests), and C2 (n=59
529 patients, log-rank test) and progression free survival (PFS) at C2 (n = 59, log-rank test).

530

531 **Figure 5: Characterising monocyte subsets in the context of immune checkpoint blockade**

532 A) (Left) UMAP plot to show monocytes from eight patients receiving ICB at baseline (C1, d0) and
533 at d21 post-treatment (C2), plus three healthy donors) and Classical clusters 1-4 and CD16+
534 monocytes (total cells n=22,116). (Right) UMAP plot to show monocytes coloured according to
535 classical and CD16+ cluster annotation assignment. B) Expression heatmap showing gene
536 expression profiles for Classical1, Classical2, Classical3, Classical4 and CD16+ monocytes
537 groups. Genes were selected to include the ten genes per classical group with the greatest log₂ fold
538 change. C) Dotplot to show key GOBP pathways enriched in Classical1-4 and CD16+ monocyte
539 groups. D) Gene expression module score for each monocyte subgroup. Score is average of
540 expression of top 50 subgroup-defining genes for each monocyte subgroup. Positive value infers
541 expression is higher than expected, and negative value lower. F) Kaplan-Meier curve to show
542 Classical4 expression score in bulk RNA-seq data above/below median expression score) at C1 and
543 OS (n = 113 patients, log-rank test) and PFS (n = 113 patients, log-rank test).

544

545 ***Supplementary Figure 1: Differentially expressed transcripts with sICB***

546 *Volcano plot to show differentially regulated transcripts in response to sICB (DESeq2 pairwise*
547 *analysis, 45 patients).*

548

549 ***Supplementary Figure 2: Transcriptional correlates of clinical response in peripheral***
550 ***monocytes from patients at baseline***

551 *Volcano plots to show transcript expression at baseline before treatment (C1) associated with*
552 *death at: A) three months; B) six months and C) twelve months after the date of commencement of*
553 *first cycle of ICB treatment (DESeq2 analysis, controlling for age, sex, and treatment type, 114*
554 *C1 patients, $P_{adj} < 0.05$).*

555

556 ***Supplementary Figure 3: Monocyte subsets and response to ICB***

557 *Boxplots to show change in monocyte subset proportion with: A) cICB (n= 29 paired patient*
558 *samples) and B) sICB (n= 24 paired patient samples) (Paired Kruskal Wallis test). C) Kaplan*
559 *Meier curve to show lymphocyte to monocyte ratio as per flow cytometry above/below median)*
560 *before treatment, C1, and overall survival (OS) (n = 57 patients) (log-rank test).*

561

562 ***Supplementary Figure 4: Single cell RNA-seq cohort details***

563

564 ***Supplementary Figure 5: scRNA-seq clustering and annotation***

565 *A) UMAP plot to show all monocytes (from eight patients receiving ICB at baseline (C1) and day*
566 *21 post-treatment (C2), plus three healthy donor individuals ('C') clustered into nine subsets*
567 *indicated by different colours (total cells n= 24,457) at resolution 0.25 with 13 dimensions. B)*
568 *Heatmap to show proportion of assigned cell types according to SingleR annotation using*

569 *expression sets including the Human Primary Cell Atlas, Monaco Immune, Immune Cell*
570 *Expression and Villani datasets. SingleR was used to compare the expression of each single cell*
571 *to that of an annotated expression set providing classification annotation. Only cell type*
572 *annotations comprising at least 1% of the total scRNA-seq population were included. Scale ('mat')*
573 *indicates proportion of cells in the subset assigned to that cell type with 1 indicating 100%. C)*
574 *UMAP plot to show Seurat subset assignment by patient ID.. 'C' denotes control samples*
575 *(comprises cells from three pooled healthy donor samples). Each point represents a cell and cells*
576 *are coloured by Seurat cluster assignment. D) Table to show summary of annotation of Seurat*
577 *monocytes clusters (Seurat clusters 0-8) with SingleR.*
578 *We removed subset 5 from downstream analysis as it was limited to patient ID7, and control*
579 *samples. Patient ID7 was removed completely from comparisons between C1 and C2 monocyte*
580 *subgroup proportion sizes.*

581

582 ***Supplementary Figure 6: Characterising monocyte subsets with scRNA-seq***

583 *A) Heatmap to show top 20 genes by log2 fold change in classical subset comprising all Classical*
584 *groups 1-4 merged (n = 21,276 cells) and CD16+ monocyte (n=840 cells) subgroups. B) Dotplot*
585 *to show GOBP pathways most significantly enriched (top 15 most significant pathways,*
586 *Padj<0.05) in classical and CD16+ monocyte subgroups.*

587

588 ***Supplementary Figure 7: Table to show hub genes for gene expression module scoring in***
589 ***scRNA-seq data.***

590

591 ***Supplementary Figure 8: Monocyte population responses to ICB***

592 *A) Boxplots to show percentage of each monocyte group per sample both before (C1) and after*
593 *(C2) ICB (n=7 paired patient samples with patient ID7 removed). B) Barplot to show proportion*
594 *of monocyte subgroups by condition across all patients (At C1 n= 9000 cells , at C2 n=9082 cells).*
595 *C) Boxplot to show percentage per samples pre and post treatment by monocyte group for sICB*
596 *patients (n=4 paired patient samples). D) Boxplot to show percentage per samples pre and post*
597 *treatment by monocyte group for cICB patients (n=3 paired patient samples). E) Boxplot to show*
598 *percentage of classical and CD16+ monocytes per patient sample (n=7 paired patient samples).*
599 *Significance performed by a paired Wilcoxon signed rank test.*

600

601

602 **Table 1:** Differentially expressed genes in MM patients versus healthy donors.

603 **Table 2:** GOBP pathways enriched comparing MM versus healthy donors.

604 **Table 3:** Baseline monocyte count associated expressed transcripts

605 **Table 4:** monocyte count associated GOBP pathways

606 **Table 5:** Differentially expressed transcripts in circulating monocytes in response to ICB at day
607 21 (C2) across both cICB and sICB patients.

608 **Table 6:** cICB associated differentially expressed transcripts

609 **Table 7:** sICB associated differentially expressed transcripts

610 **Table 8:** GOBP pathways enriched across induced and suppressed transcripts following ICB at
611 day 21 (C2).

612 **Table 9:** Differentially expressed transcripts preferentially induced at day 21 (C2) in those
613 receiving cICB versus sICB.

614 **Table 10:** GOBP pathways enriched across transcripts preferentially induced in response to cICB
615 versus sICB.

616 **Table 11:** Transcripts differentially associated with death at three months after starting ICB
617 (C1&C2, sICB and cICB).

618 **Table 12:** Transcripts differentially associated with death at six months after starting ICB
619 (C1&C2, sICB and cICB).

620 **Table 13:** Transcripts differentially associated with death at twelve months after starting ICB
621 (C1&C2, sICB and cICB).

622 **Table 14:** GOBP pathways enriched across transcripts associated with death at three months after
623 starting ICB (C1&C2, sICB and cICB).

624 **Table 15:** GOBP pathways enriched across transcripts associated with death at six months after
625 starting ICB (C1&C2, sICB and cICB).

626 **Table 16:** GOBP pathways enriched across transcripts associated with death at twelve months
627 after starting ICB (C1&C2, sICB and cICB).

628 **Table 17A:** Transcripts differentially associated with death at three months after starting ICB (C1
629 pre-treatment only, sICB and cICB).

630 **Table 17B:** Transcripts differentially associated with death at six months after starting ICB (C1
631 pre-treatment only, sICB and cICB).

632 **Table 17C:** Transcripts differentially associated with death at twelve months after starting ICB
633 (C1 pre-treatment only, sICB and cICB).

634 **Table 18A:** Transcripts differentially associated with six month progression (C1&C2, sICB and
635 cICB).

636 **Table 18B:** GOBP pathways enriched across transcripts associated with disease progression
637 within six months of starting ICB (C1&C2, sICB and cICB).

638 **Table 19:** Transcripts defining monocyte subgroups (Classical1, Classical2, Classical3,
639 Classical4, CD16+ monocytes).

640 **Table 20:** Transcripts defining classical monocytes versus CD16+ monocytes with scRNA-seq.

641 **Table 21:** GOBP pathways enriched across transcripts defining monocyte subgroups (Classical 1-
642 4, CD16+ monocytes)

643 **Table 22:** GOBP pathways enriched across transcripts defining merged large classical group and
644 CD16+ monocytes.

645 **Tables 23-28:** to show cohort details for scRNA-seq data and significantly correlated genes across
646 scRNA-seq data with hub gene (pearson's correlation, adjusted for multiple testing).

647

648 **Author contributions**

649 BPF conceived and oversaw the study. MPF, RAW, WY, MM recruited patients. RAW annotated
650 clinical outcome data. RAC, CT, RAW, OT, AVA, PKS, EM, SD and SK collected patient samples
651 and isolated CD14+ cells. RAC and RAW performed the scRNA-seq experiments. CT, OT, EM
652 and AVA performed bulk RNA-seq experiments. IN performed bioinformatic pre-processing of
653 bulk RNA-seq and scRNA-seq data. CAT performed flow cytometry experiments. RAC performed
654 computational analysis of the bulk RNA-seq, scRNA-seq and flow cytometry data. RAC produced
655 figures and RAC and BPF drafted the manuscript.

656

657 **Acknowledgments and Funding**

658 We acknowledge and thank all the patients who donated material for this study. We thank the
659 teams at the Day Treatment Unit at the Oxford Cancer Centre for facilitating this study.

660 This work was funded by a Wellcome Trust Intermediate Clinical fellowship held by BPF (no.
661 201488/Z/16/Z), which also supported IN, SD and AVA. RAC was funded by CRUK Clinical
662 Research Training Fellowship (S_3578). CAT was funded by the Engineering and Physical
663 Sciences Research Council and Balliol Jowett Society (no. D4T00070). RAW was funded by a

664 Wellcome Trust Doctoral Training Fellowship (no. BST00070). OT was funded by the Clarendon
665 Fund, Oxford Australia Fellowship and St Edmund's Hall. WY was supported by an NIHR ACF
666 and a CRUK Predoctoral Fellowship (ref. RCCTI100019). MM and BPF are supported by the
667 NIHR Oxford Biomedical Research Centre.

668

669

670

671

672 **References**

673

- 674 1. Larkin, J. *et al.* Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
675 *New England Journal of Medicine* **381**, 1535–1546 (2019).
- 676 2. Hodi, F. S. *et al.* Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced
677 melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol* **19**,
678 1480–1492 (2018).
- 679 3. Ye, W. *et al.* Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic
680 melanoma and distinct T-cell expression profiles. *Br J Cancer* 1–9 (2021) doi:10.1038/s41416-021-01310-3.
- 681 4. Fairfax, B. P. *et al.* Peripheral CD8+ T cell characteristics associated with durable responses to immune
682 checkpoint blockade in patients with metastatic melanoma. *Nature Medicine* vol. 26 193–199 Preprint at
683 <https://doi.org/10.1038/s41591-019-0734-6> (2020).
- 684 5. Watson, R. A. *et al.* Immune checkpoint blockade sensitivity and progression-free survival associates with
685 baseline CD8+ T cell clone size and cytotoxicity. *Sci Immunol* **6**, (2021).
- 686 6. Chasseuil, E. *et al.* Blood predictive biomarkers for nivolumab in advanced melanoma. *Acta Derm Venereol*
687 **98**, 406–410 (2018).
- 688 7. Soyano, A. E. *et al.* Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung
689 Cancer patients treated with anti-PD-1 antibodies. *J Immunother Cancer* **6**, 129 (2018).
- 690 8. Ziegler-Heitbrock, L. *et al.* Nomenclature of monocytes and dendritic cells in blood. *Blood* vol. 116 Preprint
691 at <https://doi.org/10.1182/blood-2010-02-258558> (2010).
- 692 9. Krieg, C. *et al.* High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. *Nat*
693 *Med* **24**, 144–153 (2018).
- 694 10. Romano, E. *et al.* Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by
695 nonclassical monocytes in melanoma patients. *Proc Natl Acad Sci U S A* **112**, 6140–6145 (2015).
- 696 11. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data
697 with DESeq2. *Genome Biol* **15**, (2014).
- 698 12. Schalper, K. A. *et al.* Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and
699 reduced clinical benefit of immune-checkpoint inhibitors. *Nat Med* **26**, 688–692 (2020).
- 700 13. Ashburner, M. *et al.* Gene ontology: Tool for the unification of biology. *Nature Genetics* vol. 25 25–29
701 Preprint at <https://doi.org/10.1038/75556> (2000).
- 702 14. Nalbant, D. *et al.* FAM20: an evolutionarily conserved family of secreted proteins expressed in
703 hematopoietic cells. *BMC Genomics* **6**, 11 (2005).
- 704 15. Karigane, D. *et al.* p38 α Activates Purine Metabolism to Initiate Hematopoietic Stem/Progenitor Cell
705 Cycling in Response to Stress. *Cell Stem Cell* **19**, 192–204 (2016).

- 706 16. Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S. & Proost, P. Overview of the mechanisms that
707 may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands.
708 *Frontiers in Immunology* vol. 8 1970 Preprint at <https://doi.org/10.3389/fimmu.2017.01970> (2018).
- 709 17. Tokunaga, R. *et al.* CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel
710 cancer therapy. *Cancer Treatment Reviews* vol. 63 40–47 Preprint at
711 <https://doi.org/10.1016/j.ctrv.2017.11.007> (2018).
- 712 18. Khan, S. *et al.* Immune dysregulation in cancer patients developing immune-related adverse events. *Br J*
713 *Cancer* **120**, 63–68 (2019).
- 714 19. Nuñez, N. G. *et al.* Immune signatures predict development of autoimmune toxicity in patients with cancer
715 treated with immune checkpoint inhibitors. *Med* **4**, 113-129.e7 (2023).
- 716 20. Chen, S. *et al.* Mechanisms regulating PD-L1 expression on tumor and immune cells. *J Immunother Cancer*
717 **7**, 1–12 (2019).
- 718 21. Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z. & Foukakis, T. Genetic, transcriptional and post-
719 translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical
720 correlations. *Oncogene* vol. 37 4639–4661 Preprint at <https://doi.org/10.1038/s41388-018-0303-3> (2018).
- 721 22. Ragland, S. A. & Criss, A. K. From bacterial killing to immune modulation: Recent insights into the
722 functions of lysozyme. *PLoS Pathog* **13**, e1006512 (2017).
- 723 23. Yeap, W. H. *et al.* CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.
724 *Sci Rep* **6**, 1–22 (2016).
- 725 24. Kapellos, T. S. *et al.* Human monocyte subsets and phenotypes in major chronic inflammatory diseases.
726 *Frontiers in Immunology* vol. 10 2035 Preprint at <https://doi.org/10.3389/fimmu.2019.02035> (2019).
- 727 25. Wan, L., Wu, C., Luo, S. & Xie, X. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer
728 Patients Undergoing Immune Checkpoint Inhibitors. *Dis Markers* **2022**, (2022).
- 729 26. Wu, Q., Tu, H. & Li, J. Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases
730 and Cancer. *Front Pharmacol* **13**, (2022).
- 731 27. Geng, H., Xu, G., Ran, Y., López, J. A. & Peng, Y. Platelet Glycoprotein Ib β /IX Mediates Glycoprotein Iba
732 Localization to Membrane Lipid Domain Critical for von Willebrand Factor Interaction at High Shear. *J*
733 *Biol Chem* **286**, 21315 (2011).
- 734 28. Trizzino, M. *et al.* EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. *Sci Adv* **7**,
735 (2021).
- 736 29. Gren, S. T. *et al.* A Single-Cell Gene-Expression Profile Reveals Inter-Cellular Heterogeneity within Human
737 Monocyte Subsets. *PLoS One* **10**, e0144351 (2015).
- 738 30. Wight, T. N. *et al.* Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation.
739 *Front Immunol* **0**, 512 (2020).
- 740 31. Tsou, C. L. *et al.* Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and
741 recruitment to inflammatory sites. *Journal of Clinical Investigation* **117**, 902–909 (2007).
- 742 32. Cassetta, L. *et al.* Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal
743 Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. *Cancer Cell* **35**, 588-602.e10
744 (2019).
- 745 33. Ramos, R. N. *et al.* CD163⁺ tumor-associated macrophage accumulation in breast cancer patients reflects
746 both local differentiation signals and systemic skewing of monocytes. *Clin Transl Immunology* **9**, (2020).
- 747 34. Qian, B. Z. *et al.* CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature* **475**,
748 222–225 (2011).
- 749 35. Ugurel, S. *et al.* Down-regulation of HLA II and costimulatory CD86/B7-2 on circulating monocytes from
750 melanoma patients. *Cancer Immunology, Immunotherapy* **53**, 551–559 (2004).
- 751 36. Gordon, I. O. & Freedman, R. S. Defective antitumor function of monocyte-derived macrophages from
752 epithelial ovarian cancer patients. *Clinical Cancer Research* **12**, 1515–1524 (2006).
- 753 37. Almand, B. *et al.* Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of
754 Immunosuppression in Cancer. *The Journal of Immunology* **166**, 678–689 (2001).
- 755 38. Lee, Y. Y. *et al.* Prognostic value of pre-treatment circulating monocyte count in patients with cervical
756 cancer: Comparison with SCC-Ag level. *Gynecol Oncol* **124**, 92–97 (2012).
- 757 39. Machida, H. *et al.* Significance of Monocyte Counts at Recurrence on Survival Outcome of Women With
758 Endometrial Cancer. *International Journal of Gynecologic Cancer* **27**, 302–310 (2017).
- 759 40. Hayashi, T. *et al.* Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive
760 factor of adverse pathology in radical prostatectomy specimens. *Prostate* **77**, 1383–1388 (2017).
- 761 41. Wen, S. *et al.* Elevated peripheral absolute monocyte count related to clinicopathological features and poor
762 prognosis in solid tumors: Systematic review, meta-analysis, and meta-regression. *Cancer Med* **10**, 1690
763 (2021).

- 764 42. Chow, M. T. *et al.* Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-
765 PD-1 therapy. *Immunity* **50**, 1498 (2019).
- 766 43. House, I. G. *et al.* Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses
767 following immune checkpoint blockade. *Clinical Cancer Research* **26**, 487–504 (2020).
- 768 44. Wen, J. *et al.* Prognostic significance of preoperative circulating monocyte count in patients with breast
769 cancer based on a large cohort study. *Medicine (United States)* **94**, (2015).
- 770 45. Wen, S. *et al.* Peripheral monocyte counts predict the clinical outcome for patients with colorectal cancer.
771 *Eur J Gastroenterol Hepatol* **31**, 1 (2019).
- 772 46. Gebhardt, C. *et al.* Myeloid cells and related chronic inflammatory factors as novel predictive markers in
773 melanoma treatment with ipilimumab. *Clinical Cancer Research* **21**, 5453–5459 (2015).
- 774 47. Kiss, M., Caro, A. A., Raes, G. & Laoui, D. Systemic Reprogramming of Monocytes in Cancer. *Frontiers in*
775 *Oncology* vol. 10 1399 Preprint at <https://doi.org/10.3389/fonc.2020.01399> (2020).
- 776 48. Villani, A. C. *et al.* Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and
777 progenitors. *Science (1979)* **356**, (2017).
- 778 49. Goudot, C. *et al.* Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus
779 Macrophages. *Immunity* **47**, 582-596.e6 (2017).
- 780 50. Vishwakarma, A. *et al.* Title: Mapping the Immune Landscape of Clear Cell Renal Cell Carcinoma by
781 Single-Cell RNA-seq. doi:10.1101/824482.
- 782 51. Zilionis, R. *et al.* Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved
783 Myeloid Populations across Individuals and Species. *Immunity* **50**, 1317-1334.e10 (2019).
- 784 52. Allen, N. *et al.* Circulating monocyte-platelet aggregates are a robust marker of platelet activity in
785 cardiovascular disease. *Atherosclerosis* **282**, 11–18 (2019).
- 786 53. Hottz, E. D. *et al.* Platelet activation and platelet-monocyte aggregate formation trigger tissue factor
787 expression in patients with severe COVID-19. *Blood* **136**, 1330–1341 (2020).
- 788 54. Passacquale, G. *et al.* Monocyte-Platelet Interaction Induces a Pro-Inflammatory Phenotype in Circulating
789 Monocytes. *PLoS One* **6**, e25595 (2011).
- 790 55. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: A fast spliced aligner with low memory requirements.
791 *Nat Methods* **12**, 357–360 (2015).
- 792 56. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing
793 data. *Bioinformatics* **31**, 166 (2015).
- 794 57. Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for RNA-seq count data.
795 *NAR Genom Bioinform* **2**, (2020).
- 796 58. Fang, H., Knezevic, B., Burnham, K. L. & Knight, J. C. XGR software for enhanced interpretation of
797 genomic summary data, illustrated by application to immunological traits. *Genome Med* **8**, 129 (2016).
- 798 59. Chromium Single Cell V(D)J Reagent Kits User Guide (v1.1 Chemistry) with Feature Barcoding technology
799 for Cell Surface Protein -User Guide -Index -Single Cell Immune Profiling -Official 10x Genomics Support.
800 [https://support.10xgenomics.com/single-cell-vdj/index/doc/user-guide-chromium-single-cell-vdj-reagent-](https://support.10xgenomics.com/single-cell-vdj/index/doc/user-guide-chromium-single-cell-vdj-reagent-kits-user-guide-v1.1-chemistry-with-feature-barcoding-technology-for-cell-surface-protein)
801 [kits-user-guide-v1.1-chemistry-with-feature-barcoding-technology-for-cell-surface-protein.](https://support.10xgenomics.com/single-cell-vdj/index/doc/user-guide-chromium-single-cell-vdj-reagent-kits-user-guide-v1.1-chemistry-with-feature-barcoding-technology-for-cell-surface-protein)
- 802 60. Release Notes for Cell Ranger 3.0 Gene Expression & Feature Barcoding -Software -Single Cell Gene
803 Expression -Official 10x Genomics Support. [https://support.10xgenomics.com/single-cell-gene-](https://support.10xgenomics.com/single-cell-gene-expression/software/release-notes/3-0)
804 [expression/software/release-notes/3-0.](https://support.10xgenomics.com/single-cell-gene-expression/software/release-notes/3-0)
- 805 61. Package ‘scater’ Title Single-Cell Analysis Toolkit for Gene Expression Data in R Description A collection
806 of tools for doing various analyses of single-cell RNA-seq gene expression data, with a focus on quality
807 control and visualization. (2021).
- 808 62. Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-
809 cell RNA-seq data with Bioconductor. *F1000Res* **5**, (2016).
- 810 63. Butler, A. & Satija, R. Integrated analysis of single cell transcriptomic data across conditions, technologies,
811 and species. *bioRxiv* 164889 Preprint at <https://doi.org/10.1101/164889> (2017).
- 812 64. Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions.
813 *Gigascience* **7**, 1–9 (2018).
- 814 65. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic
815 macrophage. *Nat Immunol* **20**, 163–172 (2019).
- 816 66. Mabbott, N. A., Baillie, J. K., Brown, H., Freeman, T. C. & Hume, D. A. An expression atlas of human
817 primary cells: Inference of gene function from coexpression networks. *BMC Genomics* **14**, 632 (2013).
- 818 67. Monaco, G. *et al.* RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution
819 of Human Immune Cell Types. *Cell Rep* **26**, 1627-1640.e7 (2019).

820 Schmiedel, B. J. *et al.* Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. *Cell* **175**, 1701-
821 1715.e16 (2018).




Figure 1












A**B****C****E****D****F**

Figure 2








Figure 4




Figure 5